Anti-Amyloid Class Labeling Could See Changes With Lilly’s Donanemab Approval

The US FDA is considering labeling that calls greater attention to the symptoms of amyloid-related imaging abnormalities to ensure proper treatment and avoid misclassification as ischemic stroke.